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Abstract: 
Introduction: Encapsulated follicular variant of papillary thyroid carcinoma [EFV-PTC] is an indolent variant of papillary 
thyroid carcinoma [PTC]. Based on capsular and vascular invasion,  EFV-PTCs are divided into non-invasive [NIEFV-PTC] 
and invasive [IEFV-PTC] subtypes. Recently, NIEFV-PTC was re-classified as a non-malignant thyroid neoplasm. This study 
evaluates the clinicopathological characteristics and management of NIEFV-PTC among patients treated at King Abdulaziz 
Medical City, Jeddah, Saudi Arabia 
Methods: A Retrospective cross-sectional study involving 44 cases of NIEFV-PTCs.  They were identified after reviewing the 
pathology reports of all thyroid gland surgeries performed from January 2011 to December 2015 at King Abdulaziz Medical 
City. Clinical data and follow up were obtained from patient's records.  
Statistical analysis used: IBM SPSS 22 [SPSS Inc., Chicago, Il, USA] was used. Chi-square and one-way ANOVA tests were used 
to delineate statistical significance.  
Results: Cases included 40 women and 4 men, with a mean age of 35-years-old. All had a unilateral tumor[s] [37 unifocal and 7 
multifocal], with an average tumor size of 3.4 cm. Histologically, these tumors were surrounded by a well- defined capsule, with 
no capsular or vascular invasion and all lacked extrathyroidal extension, perinural invasion, positive resection margins, and/or 
high mitotic activity.  No lymph node or distant metastases were identified.  Patients were treated by total thyroidectomy [n=24], 
completion thyroidectomy [n=19], or lobectomy [n=1] combined with radioactive iodine ablation in 25 patients with a mean 
dose of 92.8 ±25.4 mCi.  A median follow-up of 19 months was available for 95.5% patient, none of them demonstrated any 
evidence of disease recurrence/metastasis.  
Conclusions:  
NIEFV-PTC is an indolent thyroid tumor with very low-likelihood of metastases.  To avoid over-treatment, we recommend the 
incorporation of the recently coined term [NIFTP] into the management algorithms for patients with thyroid tumors.  
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INTRODUCTION: 
The incidence of thyroid cancers has increased up to 
3 times over the past few decades, in particular,  the 
most common histologic type called papillary thyroid 
carcinoma [PTC].[1–7] If the latter trend continues, it 
is predicted that by 2030 it will be the fourth most 
common cancer among both genders worldwide.[8] 
In Saudi Arabia, thyroid cancer is the second most 
common cancer in females following breast 
cancer.[7]  
Encapsulated follicular variant of papillary thyroid 
carcinoma [EFV-PTC] is a common subtype of PTC. 
It is architecturally similar to follicular thyroid 
neoplasms, however, it displays nuclear features of 
PTC. Based on capsular and vascular invasion they 
are further divided into non-invasive and invasive 
subtypes [NIEFV-PTC] and [IEFV-PTC], 
respectively.[9]  
 
Follow-up studies of patients with NIEFV-PTC 
demonstrated a very low-risk of recurrence or 
metastases despite being treated by either surgery 
alone or in combination with radioactive iodine 
ablation.[10–16] In 2016, a group of international 
experts in thyroid cancer proposed that NIEFV-PTC 
be reclassified as a non-malignant thyroid neoplasm 
and to use the term: “Noninvasive Follicular Thyroid 
Neoplasm with Papillary-Like Nuclear Features 
[NIFTP]” instead. This reclassification was based on 
characteristic clinical, morphological, and molecular 
features.[10] The purpose of our study was to 
evaluate the clinicopathological characteristics and 
management of NIEFV-PTC among patients 
attending a tertiary care institute in Saudi Arabia.  
 
MATERIAL AND METHODS: 
After obtaining institutional ethical research board 
approval, we retrieved 309 cases of thyroid gland 
malignancies from the Pathology archives at King 
Abdulaziz Medical City, Jeddah, Saudi Arabia, from 
January 2011 to December 2015. The pathology 
reports were retrospectively reviewed and a total of 
248 cases were included and categorized as follows: 
classical papillary thyroid carcinoma [C-PTC] 
[n=179, 72%], NIEFV-PTC [n=44, 18%], and IEFV-
PTC [n=25, 10%]. Other variant of PTC, incidental 
papillary microcarinoma [1 cm] and other types of 
thyroid malignancies [eg, follicular, medullary, 
anaplastic, and lymphoma] were excluded. 
The diagnostic criteria used for diagnosis of these 
tumors were based on the 2004 WHO/IARC 
Classification of Endocrine Tumors.[17] All 
Histopathology related diagnostic materials and 
slides were examined with an Olympus BX53 
microscope [U-DO model, Olympus, Waltham, MA] 
by a board certified pathologists and all thyroid 
specimens were adequately sampled with a mean of 
13.4 blocks submitted per specimen. This study 
focuses on NIEFV-PTC; however, we evaluated C-
PTC and IEFV-PTC for comparison.  
Pathological data obtained were according to the 
following variables: maximum tumor size in cm, 
architectural pattern of growth, focality and laterality, 
tumor encapsulation, capsular invasion [defined as; 
complete transgression of` the capsule], vascular 
invasion [presence of endothelialized tumor within 
the capsular or extra-capsular vessels with or without 
fibrin thrombus], perinural invasion, extra-thyroidal 
extension into perithyroidal soft tissue stroma, 
margin status, and pathological [TNM] tumor 
staging.  
 
The patient’s records were reviewed for the following 
variables: gender, age at diagnosis, treatment, and 
follow up, which was based on patient’s history, 
clinical examination, significant elevation in serum 
thyroglobulin, and radiological findings.  
 
For statistical analysis, IBM SPSS 22 [SPSS Inc., 
Chicago, Il, USA] was used. Chi-square and one-way 
ANOVA tests were used to delineate statistical 
association between categories and means, 
respectively. Level of significance was determined at 
p< 0.05.  
 
RESULTS: 
The mean age for all 248 cases was 42-years-old 
[range: 8–87 years], majority of which were females 
[n= 204] with a male-to-female ratio of 1:4.6. Table 1 
lists the clinical and pathological features of NIEFV-
PTC, IEFV-PTC, and C-PTC. Using one-way 
ANOVA, it was found that the difference between 
mean age and maximum tumor size of the study 
groups was significant [P=0.001] and [P=0.001] 
respectively. Post hoc analysis showed that NIEFV-
PTCs affected younger age group [mean=35 years 
±13] than IEFV-PTCs [P=0.046] and C-PTCs 
[P=0.003], where IEFV-PTCs and C-PTCs presented 
in similar age group. NIEFV-PTCs had larger 
maximum tumor size than C-PTCs [P=0.013], but no 
difference was found between the size of NIEFV-
PTCs and IEFV-PTCs. NIEFV-PTCs tended to be 
unilateral [P=0.001] and unifocal [P=0.028] 
compared to IEVFV-PTC and C-PTC. Histologically, 
all NIEFV-PTCs were characterized by a well-
formed tumor capsule, with no capsular or vascular 
invasion and absence of extrathyroidal extension, 
perinural invasion, and positive margins. Lymph 
node and distant metastases were not identified.  
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Table 1: Clinical and pathological features of C-PTCs, NIEFV-PTCs, and IEFV-
PTCs among the studied patients 
Feature C-PTC 
[n=179], n[%] 
NIEFV-PTC 
[n=44], n[%] 
IEFV-PTC 
[n=25], n[%] 
P 
Mean Age ± SD 
[years] 
43±15 35±13 44±14 P=0.00
4a 
 
Gender    
- Female  
- Male  
 
142 [79.3] 
37[20.7] 
 
40 [90.9] 
4 [9.1] 
 
22 [88] 
3 [12 ] 
 
Average tumor size ± 
SD [in cm] 
2.55 ± 1.77 3.41 ± 1.88 3.71 ± 1.95 P=0.00
1a 
Focality  
- Unifocal 
- Multifocal 
 
113 [63.1] 
66  [36.9] 
       
37 [83.7] 
7  [16.3] 
 
16 [64] 
9 [ 36] 
 
P=0.02
8b 
Laterality 
- Unilateral 
- Bilateral 
 
134 [74.9] 
45 [25.1] 
 
44 [100] 
0 
 
19[88] 
6 [12] 
 
P=0.00
1b 
Encapsulation  
- Complete  
- Partial  
- Absent 
 
25 [14] 
12 [6.7] 
142 [79.3] 
 
44 [100] 
0 
0 
 
25 [100] 
0 
0 
 
Invasion 
- Capsular 
- Vascular 
- Perinural 
 
17 [10] 
34 [19] 
8 [4.5] 
 
0 
0 
0 
 
25 [100] 
7 [28] 
1 [4] 
 
Extra-thyroidal 
extension 
- Present  
- Absent 
 
44 [24.7] 
135 [75.3] 
 
0 
44 [100] 
 
2 [8] 
23 [92] 
 
Margin status 
- Positive 
- Negative  
 
42 [23.5] 
137 [76.5] 
 
0 
44 [100] 
 
3 [12] 
22 [88] 
 
Abbreviations: C-PTC, classic Papillary carcinoma; NIEFV-PTC, non-invasive 
encapsulated folli5ular variant of papillary thyroid carcinoma; IEFV-PTC, 
invasive encapsulated follicular variant of papillary thyroid carcinoma. 
a one-way ANOVA test 
b Chi-square test   
Level of significance was determined at p< 0.05. 
 
 
Tumor staging and treatment of NIEFV-PTC cases are summarized in table 2. Post-operative radioactive active 
iodine ablation was administered for 67% of C-PTCs, 68% of IEFV-PTCs, 56.8% of NIEFV-PTCs with a mean 
dose of 127.7 ±59.6 mCi, 108.7 ±44.3 mCi, 92.8 ±25.4 mCi, respectively. A median follow-up of 24 months was 
available for 227 [91.5%] patients. None of NIEFV-PTC cases demonstrated any evidence of disease recurrence, 
regardless of treatment status by radioactive iodine therapy. However, eight cases of C-PTCs and one of the IEFV-
PTCs had an evidence of disease recurrence or metastasis.  
 
 
Table 2: TNM tumor staging and treatment of  NIEFV-PTC 
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DISCUSSION: 
Papillary thyroid carcinomas account for 90% of all 
annually diagnosed thyroid malignancies with better 
prognostic outcome compared to other 
tumors.[2,6,17] Encapsulated follicular variant of 
papillary thyroid carcinoma [EFV-PTC], a 
challenging and controversial entity, is a common 
subtype of PTC with low malignant 
potential.[11,12,18] Its incidence has been reported to 
increase by 2 to 3 fold over the past few decades, 
representing 10% to 20% of all thyroid malignancies 
diagnosed in Europe and North America.[19,20] 
Morphologically, they are characterized by 
predominance of follicular architecture, follicular 
cells with nuclear changes resembling those in 
classical papillary thyroid carcinoma and a peripheral 
capsule. Based on capsular and/or vascular invasion, 
EFV-PTC can be either invasive or non-invasive.[9] 
Their molecular analysis showed a high prevalence of 
RAS mutations, which are frequent in follicular 
adenoma and follicular carcinoma.[21,22]  
The recently emerging data reporting the benign 
behavior and the potential for over-treatment and 
costs of treatment for NIEFV-PTC has created, 
amongst other concerns, a major public concern.[23] 
Invasion rather than nuclear features of PTC was the 
major determinant of biological behaviour.[10–12,24] 
This has led to a paradigm shift in the classification, 
diagnosis, and management of these tumors. The  
 
 
 
harbinger of this shift was a proposal by an 
international panel of pathologists and clinicians who 
proposed to re-classify NIEFV-PTC as a non-
malignant thyroid neoplasm and to use the term: 
“Noninvasive Follicular Thyroid Neoplasm with 
Papillary-Like Nuclear Features [NIFTP]”.[10] Based 
on the re-classification, NIFTP are best managed 
conservatively by surgery alone without radioactive 
iodine therapy.[9,11,12,18,25]  
 
In keeping with recent studies that indicated the 
indolent behavior of NIEFV-PTC, none of our cases 
displayed vascular invasion, perinural invasion, 
extra-thyroidal extension, positive margins, lymph 
node or distant metastases. All our cases 
demonstrated no evidence of disease after a median 
follow up of 19 months, regardless of receiving 
radioactive iodine therapy. This outcome is consistent 
with previous studies that were able to follow up 
patients for a median follow up of more than 9.5 
years.[10–12, 24]  
 
The impact of the recent paradigm shift has major 
repercussions on the overall management of thyroid 
cancer. The obvious impact is on the pre-operative 
diagnosis of thyroid nodules by fine-needle-
aspiration using The Bethesda System for Reporting 
Thyroid Cytology [TBSRT] criteria, particularly for 
criteria used for follicular-patterned lesions. Different 
 NIEFV-PTC 
[n=44], n[%] 
Tumor T stage  
- pT1a 
- pT1p 
- pT2 
- pT3 
Tumor N stage 
- Nx 
- N0 
Tumor M stage  
- M0 
 
3 [6.8] 
11 [25] 
19 [43] 
11 [25] 
 
       31 [70.5] 
13 [29.5] 
 
44 [100] 
Thyroid surgery 
- Lobectomy 
- Total thyroidectomy 
- Completion thyroidectomy 
 
1 [2.3] 
24 [54.5] 
19 [43.2] 
Received RAI therapy 25 [56.8] 
Mean dose of RAI therapy ± SD [mCi]  
[Range]  
92.8 ± 25.4 
[30-150] 
 
Abbreviations: NIEFV-PTC, non-invasive encapsulated follicular 
variant of papillary thyroid carcinoma; RAI, radioactive iodine; mCi, 
millicurie 
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studies have demonstrated that the rate of definitive 
diagnosis of follicular variant of papillary thyroid 
carcinoma is low, ranging from 9.8% to 37.5%.[26–
28]  The main strength of TBSRT its ability to predict 
a risk of malignancy [ROM] for each of its diagnostic 
categories. This ROM would further assist in the 
management of patients with thyroid nodules in 
conjunction with clinical and radiological features. 
The NIEFV-PTC comprise a significant proportion of 
cases in the indeterminate category of the TBSRT, 
which include: atypia of undetermined 
significance/follicular lesion of undetermined 
significance, follicular neoplasm/suspicious for 
follicular neoplasm, and suspicious for malignancy. 
Changing the diagnosis of NIEFV-PTC to NIFTP 
will likely decrease the ROM for these categories. 
Further, these changes may be reflected in further 
updates to the current TBSRTC.[29–31]  
Furthermore, the rate of diagnosis of thyroid tumors 
may decrease and the management may experience a 
shift in surgical and medical options of treatment 
based on this new recommendation. When the 
NIEFV-PTC is viewed as a malignant neoplasm, 
staging would be performed according to malignant 
thyroid tumor protocols and treatment decisions 
would be based on this perspective. This may lead to 
over-treatment of these indolent tumors and major 
medical, surgical, psychological, financial, and 
medicolegal issues.[32–34]  
 
Limitations to our study include that it is a 
retrospective study of patients treated in a tertiary 
care center, thus referral bias cannot be excluded. 
Larger nationwide and international studies based on 
data from tumor registries would be helpful to further 
establish local/regional guidelines for diagnosis and 
management of patient with NIFTP diagnosis. Our 
study further lacks molecular characterization of 
these tumors. Utilization of new molecular 
techniques could be helpful and may be considered in 
a future study.  
 
In Conclusion, NIEFVPTC is an indolent thyroid 
tumor. The recent NIFTP nomenclature and re-
classification of this tumor represent a paradigm shift. 
We recommend further studies involving larger-
cohorts of patients, as well as, adoption of most 
recent guidelines in the diagnosis and management 
algorithms of patients with thyroid tumors to avoid 
potential over-treatment. 
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